Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040

TENAX THERAPEUTICS, INC.

EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.
European patent protection through at least December 2040, with potential SPC extension beyond.
Patent also covers active metabolites OR1896/OR1855 and combination with other cardiovascular drugs.
Builds on existing U.S. and Canada patents; supports Phase 3 LEVEL-2 study initiation expected this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.